Early Aspirin Withdrawal After PCI in ACS: NEO-MINDSET and TARGET Trials
Christopher Cannon, Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital, shared a post on LinkedIn:
”Keep the ASA for the first 12 months post ACS PCI.
The NEO-MINDSET trial found that early stopping and keeping P2Y12 monotherapy was NOT sufficient for efficacy.
Of note, another study published, the TARGET First looked at “low risk” STEMI patients and suggested one could stop ASA, but it appeared to have much less power with just 41 primary endpoints.
So – I will aim to keep DAPT for a year post PCI for ACS. (although sometimes one has to adapt for very high risk bleeding patients).”
Title: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
Authors: Patricia O. Guimarães, Marcelo Franken, Caio A.M. Tavares, Murillo O. Antunes, Fabio S. Silveira, Pedro B. Andrade, Ricardo R. Bergo
Read the full article here.
Find more on Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera